Results 101 to 110 of about 72,405 (280)
Infliximab therapy in pediatric Crohn’s disease: a review
Kalyan Ray Parashette1, Raghavendra Charan Makam2, Carmen Cuffari31Department of Pediatrics, University of Illinois at Chicago, Chicago, IL, USA; 2Department of Internal Medicine, Berkshire Medical Center, Pittsfield, MA, USA; 3Division of Pediatric ...
Carmen Cuffari +2 more
core
Abstract Objective Evaluating clinical practices in the management of non‐esophageal eosinophilic gastrointestinal disorders (non‐EoE EGIDs) among pediatric gastroenterologists in Latin America. Methods A cross‐sectional descriptive study was conducted using a survey distributed via the REDCap platform.
Sofia Paz +17 more
wiley +1 more source
The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis
Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
Jonathan Van Hecke +7 more
wiley +1 more source
Infliximab‐induced autoimmune hepatitis requiring liver transplantation
Autoimmune hepatitis is an infrequent but significant side effect of infliximab treatment. Diagnosis of autoimmune hepatitis is based on clinical, laboratory, and histological findings.
Frederick Wong +3 more
doaj +1 more source
Abstract Commercial payers and pharmacy benefit managers use site‐of‐care and specialty drug distribution policies (including white bagging and brown bagging) that can redirect infusion‐based biologic therapies from hospital outpatient departments to alternate settings.
Brad Pasternak
wiley +1 more source
Human immunodeficiency virus infection mimicking very early onset inflammatory bowel disease
Abstract Very early onset inflammatory bowel disease (VEO‐IBD), defined as diagnosis before 6 years of age, is often associated with immune dysregulation and monogenic etiologies; however, infectious mimics may be overlooked in low‐prevalence regions. We report a 4‐year‐old male with poor weight gain, intermittent diarrhea, elevated fecal calprotectin,
Rasha Abi Radi Abou Jaoudeh +2 more
wiley +1 more source
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
Smriti Subedi,1,2,* Yu Gong,1,2,* Youdong Chen,1,2, Yuling Shi1,21Department of Dermatology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, People’s Republic of China; 2Department of Dermatology ...
Subedi S, Gong Y, Chen Y, Shi Y
doaj
The Ab lock can prevent the response of the anti-Id Ab to Infliximab.
(A) The anti-I-Id Ab–coated 96-well plate was incubated with different concentrations of Infliximab-biotin (○), pro-Infliximab-biotin (□), Infliximab-biotin preincubated with MMP-2/9 (●), or pro-Infliximab-biotin preincubated with MMP-2/9 ...
Kai-Wen Cheng (4583350) +13 more
core +1 more source
Abstract Objectives Children with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), experience a significantly lower health‐related quality of life (HRQoL) compared to healthy children. Over the past decade, advancements in IBD care may have influenced HRQoL. The aim of this study was to compare HRQoL between
Johanna M. B. W. Vos +6 more
wiley +1 more source
Pierpaolo Di Micco1,2, Paola Ferrazzi1, Luca Librè1, Loredana Mendolicchio1, Ilaria Quaglia1, Monica De Marco1, Anna Colombo1, Monica Bacci1, Lidia Luciana Rota1, Corrado Lodigiani11Thrombosis Center, Istituto Clinico Humanitas, Rozzano (MI ...
Luca Librè +3 more
core

